ABOS

Conviction 41HealthcareScan · Thu, Jun 25, 2026

ABOS$2.20-4.76%

ResistanceSupportVol 14Insider sell

Vol MA14 446.43K

Mar 26Apr 14May 1May 19Jun 8Jun 25

Acumen Pharmaceuticals, Inc.BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)www.acumenpharm.com ↗

Price2.20

Change-4.76%

Gap+0.65%

Rel volume1.72×

Avg volume401.69K

Avg $ vol928.77K

SMA 202.33

SMA 502.44

SMA 2002.25

Price vs 50-9.81%

Price vs 200-2.16%

MA stackmixed

50/200 cross—

Supertrendup · 2.14

RSI (14)41

MACD hist0.01

MACD crossbull · 8d

Stoch %K / %D22 / 49

ADX (14)10

+DI / −DI18 / 24

RSI divergence—

MACD divergence—

ATR %+6.84%

ADR %6.10%

52w high3.37

52w low1.11

From 52w high-34.72%

Above 52w low+98.20%

New 52w highNo

SqueezeOff

Bollinger width20.50%

%B0.23

Donchian pos15.62%

Donchian high2.66

Donchian low2.12

AVWAP (52w high)2.73

vs AVWAP high-19.36%

AVWAP (52w low)2.29

vs AVWAP low-3.87%

OBV trendFlat

Chaikin MF (20)-0.55

Today vs 20d1.72×

Avg vol (14d)446.43K

Avg vol (20d)401.69K

Avg $ vol (20d)928.77K

Market cap158.9M

RS 3m (vs SPY)-23.07%

RS 6m (vs SPY)-0.29%

RS line new highNo

Trend template4/8

Technical rank30.4

1 week-2.22%

1 month-9.09%

3 months-16.35%

6 months-3.51%

1 year+74.60%

YTD+8.91%

P/E-1.31

P/B1.82

P/S—

P/FCF-1.37

EPS-2.00

Div yield—

ROE-138.71%

ROA-90.80%

Debt/Eq0.35

Current4.55

EV/EBITDA—

Gross margin—

Net margin—

Rev growth—

EPS growth-18.57%

Price target—

Target upside—

Analyst rating—

Institutional—

Ent. value138.15M

Revenue—

Net income-20.74M

Gross profit—

Free cash flow-115.63M

IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

ExchangeNasdaq

Shares out72.23M

Employees61

ListedThu, Jul 1, 2021

Free float37.43M

Float %51.8%

Short interest1.89M

Days to cover5.5d

Short volume64.9%

Squeeze score62 / 100

Next earnings—

EPS forecast—

Last EPS vs est—

Last surprise—

Setup gradeD

Conviction41 / 100

Pattern quality—

Tech rank30.4 / 100

Group rank50 / 100

Status laneNo active setup

Setup direction—

Pattern family

Resistance2.70

Support2.10

Days since event—

Candle confirm—

News sentiment—

Financials as of Tue, Mar 31, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in ABOS

All disclosures →

No recent disclosed trades by Congress in ABOS. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in ABOS · 4 buys · 6 sells

Insider	Side	Shares	Value	Traded	Filed
Porter Derrell Director · Stock Option (right to buy) · 2026-06-17	Exercise	13.04K	—	2026-06-17	2026-06-17
Porter Derrell Director · Common Stock · 2026-06-17	Exercise	13.04K	$14K	2026-06-17	2026-06-17
Porter Derrell Director · Common Stock · 2026-06-17	Sell	13.04K	$30K	2026-06-17	2026-06-17
Porter Derrell Director · Common Stock · 2026-06-16	Sell	12.8K	$30K	2026-06-16	2026-06-17
Porter Derrell Director · Common Stock · 2026-06-15	Exercise	6.46K	$7K	2026-06-15	2026-06-17
Porter Derrell Director · Stock Option (right to buy) · 2026-06-15	Exercise	6.46K	—	2026-06-15	2026-06-17
Porter Derrell Director · Common Stock · 2026-06-15	Sell	6.46K	$15K	2026-06-15	2026-06-17
Fountain Nathan B Director · Common Stock · 2026-06-09	Sell	6.4K	$14K	2026-06-09	2026-06-10
Porter Derrell Director · Stock Option (right to buy) · 2026-06-03	Grant	53.25K	$0	2026-06-03	2026-06-05
Fountain Nathan B Director · Stock Option (right to buy) · 2026-06-03	Grant	53.25K	$0	2026-06-03	2026-06-05

SEC filings

EDGAR filings in ABOS · 6 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, cancel in one click.

Start free — 7-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.